Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

121. Relationship between osteoporosis and periodontitis still unclear

Relationship between osteoporosis and periodontitis still unclear Relationship between osteoporosis and periodontitis still unclear ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted business products Purchase ADA products Access oral-health (...) information for the public and ADA Find-A-Dentist Partnerships and Commissions Learn about ADA CERP recognition, look up CERP recognized CE providers and find CE courses. Explore CODA's role and find accredited schools and programs Learn about the examinations used in licensing dentists and dental hygienists Learn about recognized dental specialties and certifying boards Evidence Education * Associated Topics Relationship between osteoporosis and periodontitis still unclear Joan Leakey Clinical Associate

2012 ADA Center for Evidence-Based Dentistry

122. Denosumab in osteoporosis-related fractures. A critical appraisal of the FREEDOM trial

Denosumab in osteoporosis-related fractures. A critical appraisal of the FREEDOM trial Vol 20. DTB: Vol 20, No 2. March - April 2012 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DTB: Vol 20, No 2. March - April 2012 DTB: Vol 20, No 2. March - April 2012 Content tools Share it Denosumab in osteoporosis-related fractures. A critical appraisal of the FREEDOM trial Denosumab has shown efficacy vs placebo in the reduction of morphometric

2012 Drug and Therapeutics Bulletin of Navarre (Spain)

123. Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms

Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms Gauthier K, Bai A, Perras C, Cunningham J, Ahuja T, Richter T, Kovacs C Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Gauthier K, Bai A, Perras C, Cunningham J, Ahuja T, Richter T, Kovacs C. Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Evidence from six placebo-controlled randomized

2012 Health Technology Assessment (HTA) Database.

124. Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report

Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report Crandall CJ, Newberry SJ, Gellad WG, Diamant A, Lim YW, Suttorp M, Motala A, Ewing B, Roth B, Timmer M, Shanman R, Shekelle PG Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Crandall CJ, Newberry SJ, Gellad WG, Diamant A, Lim YW, Suttorp M, Motala A, Ewing B, Roth B, Timmer M, Shanman R, Shekelle PG. Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review

2012 Health Technology Assessment (HTA) Database.

125. Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines

Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines CADTH Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Denosumab and zoledronic acid were shown to be safe

2012 Health Technology Assessment (HTA) Database.

126. Review: Teriparatide reduces fractures in postmenopausal women with osteoporosis. (Abstract)

Review: Teriparatide reduces fractures in postmenopausal women with osteoporosis. 22986396 2012 12 03 2012 09 18 1539-3704 157 6 2012 Sep 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Review: teriparatide reduces fractures in postmenopausal women with osteoporosis. JC3-4 10.7326/0003-4819-157-6-201209180-02004 Johnson Bruce E BE eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 Int J Clin Pract. 2012 Feb;66(2):199-209 22257045 2012 9 19 6 0 2012 9

2012 Annals of Internal Medicine

127. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis Full Text available with Trip Pro

Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis Kingkaew P, Maleewong U, Ngarmukos C, Teerawattananon Y (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study assessed the cost-effectiveness of strategies of systematic screening for osteoporosis among postmenopausal women and medical treatments for those diagnosed positive. The authors

2012 NHS Economic Evaluation Database.

128. Denosumab and Zoledronic Acid for Patients with Postmenopausal Osteoporosis: A Review of the Clinical Effectiveness, Safety, Cost Effectiveness, and Guidelines

Denosumab and Zoledronic Acid for Patients with Postmenopausal Osteoporosis: A Review of the Clinical Effectiveness, Safety, Cost Effectiveness, and Guidelines Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH (...) and used for non-commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Denosumab and Zoledronic Acid for Patients with Postmenopausal Osteoporosis: A Review of the Clinical Effectiveness, Safety, Cost Effectiveness, and Guidelines

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

129. Bisphosphonates for Osteoporosis - Where Do We Go from Here? Full Text available with Trip Pro

Bisphosphonates for Osteoporosis - Where Do We Go from Here? 22571168 2012 06 05 2013 01 11 1533-4406 366 22 2012 May 31 The New England journal of medicine N. Engl. J. Med. Bisphosphonates for osteoporosis--where do we go from here? 2048-51 10.1056/NEJMp1202619 Whitaker Marcea M Division of Reproductive and Urologic Products, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, USA. Guo Jia J Kehoe Theresa T Benson George G eng Journal Article 2012 05 09 United (...) States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM Bone Density drug effects Bone Density Conservation Agents pharmacology therapeutic use Diphosphonates pharmacology therapeutic use Fractures, Bone epidemiology prevention & control Humans Osteoporosis drug therapy Risk Spinal Fractures epidemiology prevention & control 2012 5 11 6 0 2012 5 11 6 0 2012 6 6 6 0 ppublish 22571168 10.1056/NEJMp1202619

2012 NEJM

130. Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long? Full Text available with Trip Pro

Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long? 22571169 2012 06 05 2018 11 13 1533-4406 366 22 2012 May 31 The New England journal of medicine N. Engl. J. Med. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? 2051-3 10.1056/NEJMp1202623 Black Dennis M DM Department of Epidemiology and Biostatistics, University of California, San Francisco, USA. Bauer Douglas C DC Schwartz Ann V AV Cummings Steven R SR Rosen Clifford J CJ eng K24 (...) AR051895 AR NIAMS NIH HHS United States Journal Article 2012 05 09 United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM Bone Density drug effects Bone Density Conservation Agents administration & dosage pharmacology Diphosphonates administration & dosage pharmacology Drug Administration Schedule Fractures, Bone epidemiology prevention & control Humans Osteoporosis drug therapy Risk Spinal Fractures epidemiology prevention & control 2012 5 11 6 0 2012 5

2012 NEJM

131. Taking Bisphosphonates For Osteoporosis Increases The Risk Of Osteonecrosis Of The Jaw Only Slightly

Taking Bisphosphonates For Osteoporosis Increases The Risk Of Osteonecrosis Of The Jaw Only Slightly UTCAT2269, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Taking Bisphosphonates For Osteoporosis Increases The Risk Of Osteonecrosis Of The Jaw Only Slightly Clinical Question In a patient currently taking oral bisphosphonates, what is the likelihood of bisphosphonates induced osteonecrosis after dental extractions (...) ? Clinical Bottom Line In patients taking oral bisphosphonates, the risk of bisphosphonate induced osteonecrosis after dental extraction is slightly increased. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Pazianas/2007 11 publications reporting 26 cases of ONJ in patients receiving bisphosphonates for the treatment of osteoporosis Systematic Review of: case reports, case series and observational studies

2012 UTHSCSA Dental School CAT Library

132. Relationship Between Osteoporosis and Periodontal Disease Has Not Been Established

Relationship Between Osteoporosis and Periodontal Disease Has Not Been Established UTCAT2217, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Relationship Between Osteoporosis and Periodontal Disease Has Not Been Established Clinical Question Do patients with osteoporosis have a higher incidence of periodontal disease than the general population? Clinical Bottom Line The relationship between osteoporosis (...) and periodontal disease cannot be established based on available data. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Martinez-Maestre/2010 35 selected trials Systematic review of clinical trials Key results Few studies have been performed to demonstrate an association between systemic osteoporosis and fractures to dental loss. Most, from the few done, have found a positive correlation (five out of seven

2012 UTHSCSA Dental School CAT Library

133. The economics of improving medication adherence in osteoporosis: validation and application of a simulation model Full Text available with Trip Pro

The economics of improving medication adherence in osteoporosis: validation and application of a simulation model The economics of improving medication adherence in osteoporosis: validation and application of a simulation model The economics of improving medication adherence in osteoporosis: validation and application of a simulation model Patrick AR, Schousboe JT, Losina E, Solomon DH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of a hypothetical behavioural intervention to improve adherence to osteoporosis medication in women starting bisphosphonate therapy. The authors concluded that behavioural interventions were likely to be cost-effective in most scenarios, especially

2012 NHS Economic Evaluation Database.

134. Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms

Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé Supporting Informed Decisions Rapid Response Report: Systematic Review Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms February 2012 CADTH Cite as: Gauthier K, Bai A, Perras C (...) , Cunningham J, Ahuja,T, Richter, T, Kovacs, C. Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2012 (Rapid Response Report: Systematic Review). Production of this report is made possible by financial contributions from Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

135. Denosumab(Prolia) for osteoporosis. New mechanism but questionable efficacy

Denosumab(Prolia) for osteoporosis. New mechanism but questionable efficacy 02/2012 Denosumab( Prolia ® ) for osteoporosis New mechanism but questionable efficacy Indications 1 Treatment of osteoporosis in postmenopausal women at increased risk of fractures. Treat- ment of bone loss associated with hormone ablation in men with prostate cancer at in- creased risk of fractures. Mechanism of action and pharmacokinetics 1 This monoclonal antibody impedes the inter- action between RANKL/RANK (...) supplements should be added to the diet if daily uptake and sun ex- posure are not sufficient. Clínical efficacy Osteoporosis in postmenopause women The FREEDOM 3 study compared denosumab 60 mg every 6 months for 3 years in 7,807 postmenopausal women with or without any previous fracture, between 60 and 90 years and with basal lumbar or hip T-scores be- tween -2.5 and -4.0. The estimated absolute average probability of fracture after 10 years was 18.6% for major osteoporotic fractures and 7.33% for hip

2012 Drug and Therapeutics Bulletin of Navarre (Spain)

136. Bone-density testing interval and transition to osteoporosis in older women. Full Text available with Trip Pro

Bone-density testing interval and transition to osteoporosis in older women. Although bone mineral density (BMD) testing to screen for osteoporosis (BMD T score, -2.50 or lower) is recommended for women 65 years of age or older, there are few data to guide decisions about the interval between BMD tests.We studied 4957 women, 67 years of age or older, with normal BMD (T score at the femoral neck and total hip, -1.00 or higher) or osteopenia (T score, -1.01 to -2.49) and with no history of hip (...) or clinical vertebral fracture or of treatment for osteoporosis, followed prospectively for up to 15 years. The BMD testing interval was defined as the estimated time for 10% of women to make the transition to osteoporosis before having a hip or clinical vertebral fracture, with adjustment for estrogen use and clinical risk factors. Transitions from normal BMD and from three subgroups of osteopenia (mild, moderate, and advanced) were analyzed with the use of parametric cumulative incidence models

2012 NEJM

137. Osteoporosis: assessing the risk of fragility fracture

Osteoporosis: assessing the risk of fragility fracture Osteoporosis: assessing the risk of Osteoporosis: assessing the risk of fr fragility fr agility fracture acture Clinical guideline Published: 8 August 2012 nice.org.uk/guidance/cg146 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful (...) in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Osteoporosis: assessing the risk of fragility fracture (CG146) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 14Contents

2012 National Institute for Health and Clinical Excellence - Clinical Guidelines

138. Osteoporosis in Men Full Text available with Trip Pro

Osteoporosis in Men We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation (...) Article navigation 1 June 2012 Article Contents Article Navigation Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline Nelson B. Watts 1Mercy Health Osteoporosis & Bone Health Services (N.B.W.), Cincinnati Ohio 45236 Search for other works by this author on: Robert A. Adler 2McGuire Veterans Affairs Medical Center and Virginia Commonwealth University School of Medicine (R.A.A.), Richmond, Virginia 23298 Search for other works by this author on: John P. Bilezikian 3Columbia University

2012 The Endocrine Society

139. Osteoporosis

Osteoporosis Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2012 American College of Obstetricians and Gynecologists

140. Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age

Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age

2012 Evidence-Based Medicine